Literature DB >> 23797465

Targeted delivery of nano-therapeutics for major disorders of the central nervous system.

Huile Gao1, Zhiqing Pang, Xinguo Jiang.   

Abstract

Major central nervous system (CNS) disorders, including brain tumors, Alzheimer’s disease, Parkinson’s disease, and stroke, are significant threats to human health. Although impressive advances in the treatment of CNS disorders have been made during the past few decades, the success rates are still moderate if not poor. The blood–brain barrier (BBB) hampers the access of systemically administered drugs to the brain. The development of nanotechnology provides powerful tools to deliver therapeutics to target sites. Anchoring them with specific ligands can endow the nano-therapeutics with the appropriate properties to circumvent the BBB. In this review, the potential nanotechnology-based targeted drug delivery strategies for different CNS disorders are described. The limitations and future directions of brain-targeted delivery systems are also discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23797465     DOI: 10.1007/s11095-013-1122-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  151 in total

Review 1.  The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery.

Authors:  D R Groothuis
Journal:  Neuro Oncol       Date:  2000-01       Impact factor: 12.300

2.  Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion.

Authors:  Kizhakke M Sindhu; Karuppagounder S Saravanan; Kochupurackal P Mohanakumar
Journal:  Brain Res       Date:  2005-07-27       Impact factor: 3.252

Review 3.  Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.

Authors:  David J Begley
Journal:  Pharmacol Ther       Date:  2004-10       Impact factor: 12.310

4.  Intranasal delivery of HMGB1-binding heptamer peptide confers a robust neuroprotection in the postischemic brain.

Authors:  Il-Doo Kim; Joo-Hyun Shin; Hye-Kyung Lee; Yin-Chuan Jin; Ja-Kyeong Lee
Journal:  Neurosci Lett       Date:  2012-07-31       Impact factor: 3.046

5.  Risk factors and cerebrovascular disease.

Authors:  J T Anderson; N P Robertson
Journal:  J Neurol       Date:  2013-02       Impact factor: 4.849

6.  HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain.

Authors:  Jung-Bin Kim; Joon Sig Choi; Young-Mi Yu; Kihoon Nam; Chun-Shu Piao; Seung-Woo Kim; Min-Hyung Lee; Pyung-Lim Han; Jong-Sang Park; Ja-Kyeong Lee
Journal:  J Neurosci       Date:  2006-06-14       Impact factor: 6.167

7.  Intranasal ginsenoside Rb1 targets the brain and ameliorates cerebral ischemia/reperfusion injury in rats.

Authors:  Tingting Lu; Yongjun Jiang; Zhiming Zhou; Xuanye Yue; Ning Wei; Zhaoyao Chen; Minmin Ma; Gelin Xu; Xinfeng Liu
Journal:  Biol Pharm Bull       Date:  2011       Impact factor: 2.233

8.  Tumor imaging by means of proteolytic activation of cell-penetrating peptides.

Authors:  Tao Jiang; Emilia S Olson; Quyen T Nguyen; Melinda Roy; Patricia A Jennings; Roger Y Tsien
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-15       Impact factor: 11.205

9.  Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals.

Authors:  Xue Ying; He Wen; Wan-Liang Lu; Ju Du; Jia Guo; Wei Tian; Ying Men; Yan Zhang; Ruo-Jing Li; Ting-Yuan Yang; De-Wei Shang; Jin-Ning Lou; Liang-Ren Zhang; Qiang Zhang
Journal:  J Control Release       Date:  2009-09-30       Impact factor: 9.776

10.  Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors.

Authors:  Hemant Sarin; Ariel S Kanevsky; Haitao Wu; Alioscka A Sousa; Colin M Wilson; Maria A Aronova; Gary L Griffiths; Richard D Leapman; Howard Q Vo
Journal:  J Transl Med       Date:  2009-06-23       Impact factor: 5.531

View more
  30 in total

Review 1.  Perspectives on Dual Targeting Delivery Systems for Brain Tumors.

Authors:  Huile Gao
Journal:  J Neuroimmune Pharmacol       Date:  2016-06-08       Impact factor: 4.147

Review 2.  Novel drug-delivery approaches to the blood-brain barrier.

Authors:  Xiaoqing Wang; Xiaowen Yu; William Vaughan; Mingyuan Liu; Yangtai Guan
Journal:  Neurosci Bull       Date:  2015-01-16       Impact factor: 5.203

Review 3.  Systemic delivery to central nervous system by engineered PLGA nanoparticles.

Authors:  Qiang Cai; Long Wang; Gang Deng; Junhui Liu; Qianxue Chen; Zhibiao Chen
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

4.  Why Have Clinical Trials of Antioxidants to Prevent Neurodegeneration Failed? - A Cellular Investigation of Novel Phenothiazine-Type Antioxidants Reveals Competing Objectives for Pharmaceutical Neuroprotection.

Authors:  Maike J Ohlow; Selina Sohre; Matthias Granold; Mathias Schreckenberger; Bernd Moosmann
Journal:  Pharm Res       Date:  2016-11-28       Impact factor: 4.200

5.  Lapatinib-incorporated lipoprotein-like nanoparticles: preparation and a proposed breast cancer-targeting mechanism.

Authors:  Li Zhang; Shuang Zhang; Shao-Bo Ruan; Qian-Yu Zhang; Qin He; Hui-le Gao
Journal:  Acta Pharmacol Sin       Date:  2014-06       Impact factor: 6.150

Review 6.  Nanomaterial-based blood-brain-barrier (BBB) crossing strategies.

Authors:  Jinbing Xie; Zheyu Shen; Yasutaka Anraku; Kazunori Kataoka; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2019-09-14       Impact factor: 12.479

Review 7.  Carbon nanotubes-based drug delivery to cancer and brain.

Authors:  Qing Guo; Xian-Tao Shen; Yuan-Yuan Li; Shun-Qing Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-10-20

8.  Polyethylene glycol modification decreases the cardiac toxicity of carbonaceous dots in mouse and zebrafish models.

Authors:  Jian-tao Chen; Hua-qin Sun; Wei-liang Wang; Wen-ming Xu; Qin He; Shun Shen; Jun Qian; Hui-le Gao
Journal:  Acta Pharmacol Sin       Date:  2015-10-12       Impact factor: 6.150

Review 9.  Delivery of therapeutic peptides and proteins to the CNS.

Authors:  Therese S Salameh; William A Banks
Journal:  Adv Pharmacol       Date:  2014-08-22

10.  Biodegradable PEG-poly(ω-pentadecalactone-co-p-dioxanone) nanoparticles for enhanced and sustained drug delivery to treat brain tumors.

Authors:  Evan M Chen; Amanda R Quijano; Young-Eun Seo; Christopher Jackson; Alexander D Josowitz; Seth Noorbakhsh; Andrea Merlettini; Ranjini K Sundaram; Maria Letizia Focarete; Zhaozhong Jiang; Ranjit S Bindra; W Mark Saltzman
Journal:  Biomaterials       Date:  2018-06-18       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.